Key Market Segments:
By Technique
-
Genomics
-
Proteomics
-
Epigenetics
-
Metabolomics
By Technology
-
Sequencing Techniques
-
NGS
-
Sanger Sequencing
-
Pyro Sequencing
-
-
qPCR
-
Immunohistochemistry
-
In Situ Hybridization
-
Microarray
By Application
-
Personalized Cancer Medicine
-
Oncological Diagnostics
-
Research
-
Cancer Research
-
Biomarker Discovery
-
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Eastern Europe
-
Poland
-
Romania
-
Hungary
-
Turkey
-
Rest of Eastern Europe
-
-
Western Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Netherlands
-
Switzerland
-
Austria
-
Rest of Western Europe
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Vietnam
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
Middle East
-
UAE
-
Egypt
-
Saudi Arabia
-
Qatar
-
Rest of Middle East
-
-
Africa
-
Nigeria
-
South Africa
-
Rest of Africa
-
Latin America
-
Brazil
-
Argentina
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the Tumor Profiling Market in 2024, holding around 45% share, driven by advanced infrastructure, high adoption of precision medicine, and strong R&D investment.
In 2024, the personalized cancer medicine application segment led with 41% revenue share, reflecting growing adoption of precision oncology and tailored treatment strategies worldwide.
Key growth is driven by technological advancements such as next-generation sequencing, liquid biopsies, and AI-integrated bioinformatics improving accuracy, personalization, and treatment recommendations in oncology diagnostics.
The Tumor Profiling Market was valued at USD 11.55 billion in 2024, supported by rising cancer prevalence and expanding applications of genomic and molecular diagnostics.
The Tumor Profiling Market is expected to grow at a CAGR of 10.04% from 2025 to 2032, fueled by precision oncology, NGS, and liquid biopsy innovations.